📊 GLSI Key Takeaways
Is GLSI a Good Investment? Thesis Analysis
Greenwich LifeSciences is a pre-revenue pharmaceutical company with severe financial distress. With $3.8M in total assets, -$6.7M annual operating cash burn, and no revenue generation, the company has less than 7 months of cash runway at current burn rates. Deteriorating EPS (-75.4% YoY) and massive negative returns (ROE -523.4%, ROA -300.4%) indicate the company is in early development with high execution risk and limited margin for error.
GLSI is a pre‑revenue biotech with sustained operating losses and an extremely small asset base, leaving it dependent on external financing. Cash of $3.81M against a trailing operating cash outflow of $6.74M implies a short runway and high dilution risk. While liabilities are low and there is no debt, fundamentals point to near‑term capital needs without offsetting revenue or profitability visibility.
Why Buy GLSI? Key Strengths
- Zero long-term debt provides financial flexibility
- Strong liquidity position (17.82x current ratio) delays immediate solvency risk
- Typical pre-revenue biotech structure appropriate for development-stage company
- Debt-free capital structure
- High current and quick ratios
- Simple, cash-heavy balance sheet
GLSI Investment Risks to Consider
- No revenue reported - fundamental absence of commercial traction in pharmaceutical sector
- Negative operating cash flow of -$6.7M with only $3.8M in cash reserves (~7 months runway)
- Deteriorating EPS declining 75.4% YoY indicates accelerating losses
- Minimal balance sheet ($3.8M assets) provides almost no buffer for setbacks
- Very limited insider activity (2 Form 4 filings in 90 days) suggests low engagement or confidence
- Short cash runway vs. burn implies dilution
- No revenue and persistent operating losses
- Going concern and clinical/regulatory execution risk
Key Metrics to Watch
- Cash burn rate and remaining runway - critical for survival assessment
- Revenue recognition milestone - path to commercial viability
- Operating loss trends and timeline to profitability
- Clinical trial progress and regulatory approval status
- Cash runway (months)
- Shares outstanding/dilution rate
GLSI Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 17.82x current ratio provides a solid financial cushion.
GLSI Profitability Ratios
GLSI vs Healthcare Sector
How Greenwich LifeSciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is GLSI Overvalued or Undervalued?
Based on fundamental analysis, Greenwich LifeSciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
GLSI Balance Sheet & Liquidity
GLSI 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Greenwich LifeSciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.69 indicates the company is currently unprofitable.
GLSI Growth Metrics (YoY)
GLSI Capital Allocation
GLSI SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Greenwich LifeSciences, Inc. (CIK: 0001799788)
📋 Recent SEC Filings
❓ Frequently Asked Questions about GLSI
What is the AI rating for GLSI?
Greenwich LifeSciences, Inc. (GLSI) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 75% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are GLSI's key strengths?
Claude: Zero long-term debt provides financial flexibility. Strong liquidity position (17.82x current ratio) delays immediate solvency risk. ChatGPT: Debt-free capital structure. High current and quick ratios.
What are the risks of investing in GLSI?
Claude: No revenue reported - fundamental absence of commercial traction in pharmaceutical sector. Negative operating cash flow of -$6.7M with only $3.8M in cash reserves (~7 months runway). ChatGPT: Short cash runway vs. burn implies dilution. No revenue and persistent operating losses.
What is GLSI's revenue and growth?
Greenwich LifeSciences, Inc. reported revenue of N/A.
Does GLSI pay dividends?
Greenwich LifeSciences, Inc. does not currently pay dividends.
Where can I find GLSI SEC filings?
Official SEC filings for Greenwich LifeSciences, Inc. (CIK: 0001799788) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is GLSI's EPS?
Greenwich LifeSciences, Inc. has a diluted EPS of $-0.85.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is GLSI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Greenwich LifeSciences, Inc. has a STRONG SELL rating with 75% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is GLSI stock overvalued or undervalued?
Valuation metrics for GLSI: ROE of -523.4% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy GLSI stock in 2026?
Our dual AI analysis gives Greenwich LifeSciences, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is GLSI's free cash flow?
Greenwich LifeSciences, Inc.'s operating cash flow is $-6.7M, with capital expenditures of N/A.
How does GLSI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -523.4% (avg: 15%), current ratio 17.82 (avg: 2).